CA
NZ
UK
AU
IND
US
Tyra Biosciences, Inc. (NASDAQ: TYRA) disclosed its recent financial results, highlighting a cash position of $353.9 million comprised of cash, cash equivalents, and marketable securities.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported a second-quarter 2026 net loss per share of $0.90, substantially outperforming the consensus estimate of $-1.26. The biopharmaceutical company also recorded its highest-ever quarterly total revenue, reaching $214 million, up from $167 million in the same period last …
Sandoz Group AG reported an impressive 8% increase in share price following positive Q2 results that surpassed analysts' expectations for its biosimilars segment. The company's performance underscores its capacity to innovate within a competitive market environment, gaining traction in the growing biosimilars sector. With …
Seres Therapeutics, Inc. (NASDAQ: MCRB) has entered into an agreement to significantly reduce its real estate footprint in Cambridge, Massachusetts, by terminating a portion of its lease immediately and the remainder by the end of this year. This action allows Seres to streamline its …
Spyre Therapeutics (NASDAQ: SYRE) posted earnings per share of $-0.74 for the quarter ended March 31, 2026, missing the consensus estimate. The loss deepens a trend of negative earnings while the stock has risen sharply year‑to‑date. Investors face a juxtaposition of strong price momentum …
Strata Critical Medical, Inc. (NASDAQ: SRTA) has reported a remarkable 60.7% year-over-year revenue increase to $72.5 million for Q2 2026. The financial results highlight the strength of Strata's business transformation strategy and its focus on clinical service expansion, attracting interest from investors identifying high-growth …
Syndax Pharmaceuticals (NASDAQ: SNDX) reported second-quarter revenue of $73 million, a remarkable 92% surge compared to the same quarter last year. This growth was primarily driven by strong performances of its key products, revumenib (Revuforj) and axatilimab (Niktimvo), with net revenues from each product …
Leadership change is significant at TELA Bio, Inc. (NASDAQ: TELA) as Heather Getz steps in as the new Chief Executive Officer, effective today. This transition follows the resignation of Antony Koblish, who has held the position since the company’s inception. The switch comes at …
TransMedics Group (NASDAQ: TMDX) reported adjusted earnings per share of $0.44 for the second quarter ended June 30, 2026, falling short of the $0.48 consensus estimate. This earnings miss occurred even as total revenue climbed 21% year-over-year to $189.9 million, driven by strong product …
Travere Therapeutics, Inc. (NASDAQ: TVTX) posted a net loss of $34.8 million for the second quarter, translating to a loss of $0.37 per share. This performance fell short of the $0.14 per share consensus estimate, signaling challenges despite promising revenue growth. FILSPARI, a new …
Please wait processing your request...